Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy")

Science

Volumn 297, Issue 5590, 2002, Pages 2260-2263

  Ricaurte, George A ^a   Yuan, Jie ^a   Hatzidimitriou, George ^a   Cord, Branden J ^a   McCann, Una D ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; DRUG DOSAGE; NEUROLOGY;

SELECTIVE SEROTONIN NEUROTOXIN;

DRUG PRODUCTS;

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE;

DRUG USER; PRIMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONINERGIC SYSTEM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; AUTORADIOGRAPHY; AXONS; BRAIN; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HALLUCINOGENS; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAPIO; PARKINSONIAN DISORDERS; SAIMIRI; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; TREMOR; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PRIMATES;

EID: 0037183866     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1074501     Document Type: Article

References (34)

1. L. D. Johnston, P. M. O'Malley, J. G. Bachman, Monitoring the Future: National Survey Results on Drug Use, 1975-2000. Volume 1: Secondary School Students; Volume 2: College Students and Adults Ages 19-40 (NIH Publication Nos. 01-4924 and 01-4925, National Institute on Drug Abuse, Bethesda, MD, 2001).
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Annual Report on the State-of-the-Drug Problem in the European Union (EMCDDA, Luxembourg, 2001), pp. 1-52.
3. S. J. Peroutka, N. Engl. J. Med. 317, 1542 (1987).
4. E. Weir, Can. Med. Assoc. J. 162, 1843 (2000).
5. A. C. Parrott, Pharmacol. Biochem. Behav. 71, 837 (2002).
6. J. W. Gibb, G. R. Hanson, M. Johnson, in Amphetamine and Its Analogs: Neuropsychopharmacology, Toxicology and Abuse, A. Cho, D. Segal, Eds. (Academic Press, New York, 1994), pp. 269-295.
7. A. R. Green, A. J. Cross, G. M. Goodwin, Psychopharmacology 119, 247 (1995).
8. G. A. Ricaurte, J. Yuan, U. D. McCann, Neuropsychobiology 42, 5 (2000).
9. U. D. McCann, Z. Szabo, U. Scheffel, R. F. Dannals, G. A. Ricaurte, Lancet 352, 1433 (1998).
10. A. C. Parrott, Hum. Psychopharmacol. Clin. Exp. 16, 557 (2001).
11. E. O'Shea, B. Esteban, J. Camarero, A. R. Green, M. I. Colado, Neuropharmacology 40, 65 (2001).
12. D. M. Stone, G. R. Hanson, J. W. Gibb, Neuropharmacology 26, 1657 (1987).
13. Materials, methods, and data from NE and motor function studies are available as supporting material on Science Online.
14. R. P. Fink, L. Heimer, Brain Res. 4, 369 (1967).
15. D. B. Calne, R. F. Peppard, Can. J. Neurol. Sci. 14 (suppl. 3), 424 (1987).
16. G. A. Ricaurte et al., JAMA 260, 51 (1988).
17. T. R. Insel, G. Battaglia, J. N, Johannessen, S. Marra, E. B. DeSouza, J. Pharmacol. Exp. Ther. 249, 713 (1989).
18. D. L. Frederick et al., Neurotoxicol. Teratol. 17, 531 (1995).
19. K. T. Finnegan et al., Brain Res. 447, 141 (1988).
20. G. A. Ricaurte, L. E. Delanney, I. Irwin, J. W. Langston, Brain Res. 446, 165 (1988).
21. M. S. Kleven, W. L. Woolverton, L. S. Seiden, Brain Res. 488, 121 (1989).
22. W. Slikker Jr. et al., Toxicol. Appl. Pharmacol. 94, 448 (1988).
23. J. Mordenti, W. Chappell, in Toxicokinetics in New Drug Development, A. Yacobi, J. Kelly, V. Batra, Eds. (Pergamon, New York, 1989), pp. 42-96.
24. U. D. McCann, M. Mertl, V. Eligulashvili, G. A. Ricaurte, Psychopharmacology 143, 417 (1999).
25. M.J. Morgan, Psychopharmacology 141, 30 (1999).
26. E. Gouzoulis-Mayfrank et al., J. Neurol. Neurosurg. Psychiatry 68, 719 (2000).
27. I. Elayan et al., Eur. J. Pharmacol. 221, 281 (1992).
28. Z. Zhao, N. Castagnoli, G. A. Ricaurte, T. Steele, M. B. Martello, Chem. Res. Toxicol. 5, 89 (1992).
29. M. Johnson et al., J. Pharmacol. Exp. Ther. 261, 447 (1992).
30. R. de la Torre et al., Br. J. Clin. Pharmacol. 49, 104 (2000).
31. M. Farré et al., Drug Alcohol Depend. 63 (suppl. 1), S46 (2001).
32. J. E. Malberg, L. S. Seiden, J. Neurosci. 18, 5086 (1998).
33. S. Mintzer, S. Hickenbottom, S. Gilman, N. Engl. J. Med. 340, 1443 (1999).
34. 3H]methoxytetrabenazine. Supported by USPHS grants DA 5707, DA 13790, DA 09487, DA 00206, and DA 10217.